Stockscreener 앱 받기
2.75
4.84%
-0.14
시장 영업 전:
2.75
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Sutro Biopharma's (STRO) Buy Rating Reiterated at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Sutro Biopharma Through 5 Analysts - Benzinga
Sutro Biopharma FY2024 EPS Forecast Increased by Wedbush - MarketBeat
Sutro Biopharma Advances Pipeline Amid Financial Losses - TipRanks
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co. - MarketBeat
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates - MSN
Sutro Biopharma Inc (STRO) Q3 2024 Earnings: Revenue Misses Esti - GuruFocus.com
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sutro Biopharma Reports 56% Response Rate in Cancer Trial, Plans 3 New Drug Applications | STRO Stock News - StockTitan
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World
Sutro Biopharma (NASDAQ:STRO) shareholders are up 16% this past week, but still in the red over the last three years - Simply Wall St
Vanguard Group Inc's Strategic Acquisition in Sutro Biopharma Inc - GuruFocus.com
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - The Manila Times
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children - Clinical Trials Arena
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Buy” from Brokerages - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average PT from Brokerages - MarketBeat
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - The Manila Times
Sutro Biopharma's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
The Manufacturers Life Insurance Company Buys 7,082 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable? - Seeking Alpha
Sutro Biopharma Inc Inc. (STRO) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Algert Global LLC Reduces Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Buys 247,694 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Piper Sandler sustains Overweight rating on Sutro Biopharma shares By Investing.com - Investing.com Canada
Sutro Biopharma retains stock target with Buy rating on key advancements - Investing.com Canada
Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights - Benzinga
Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive - Simply Wall St
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
After-Market Gains For Sutro Biopharma (STRO) Following An Investor Webcast - Stocks Telegraph
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewswire
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average Price Target from Analysts - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by ProShare Advisors LLC - Defense World
Cubist Systematic Strategies LLC Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Millennium Management LLC Has $12.78 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
It would be worthwhile to take a closer look at Sutro Biopharma Inc (STRO) - US Post News
Financial Metrics Unveiled: Sutro Biopharma Inc (STRO)’s Key Ratios in the Spotlight - The Dwinnex
American Century Companies Inc. Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Susquehanna Fundamental Investments LLC Grows Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Renaissance Technologies LLC Buys 233,700 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
A better buy-in window may exist right now for Sutro Biopharma Inc (STRO) - SETE News
XTX Topco Ltd Has $95,000 Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Increases Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Investing in Sutro Biopharma Inc (STRO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Sutro Biopharma's SWOT analysis: ADC developer's stock faces pivotal year By Investing.com - Investing.com Canada
3.66%
1.11%
자본화:
|
볼륨(24시간):